Clinical Trial Search

Primary: Survival — 15 Participants — p=<0.0001

Primary: The Incidence of TA-TMA. — 5; 15 Participants

Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses

Primary: Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau) — 14934.65; 20089.79; 36208.37 µg*h/mL

Primary: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA — 0; 0; 27 Participants

Primary: Delayed Kidney Graft Function — 5; 7 Participants

Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants

Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min

Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32

Primary: Patients Treated With Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) Achieving at Least a Partial Remission (PR) at 6 Months — 9 participants

Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio

Primary: Number of Patients Alive — 7; 13 Participants

Primary: Number of Subjects Not Experiencing Grade II-IV Acute Graph Versus Host Disease (aGVHD) — 3; 18; 0 Participants

Primary: Early Allograft Dysfunction — 6; 18 Participants

Primary: Bleeding Within 30 Days — 73; 78 Participants

Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV

Primary: Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100 — 37.3 Percentage of patients developing aGVHD

Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants

Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants

Primary: Incidence of Chronic GVHD — 5 number participants with chronic GVHD

Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm

Primary: Incidence of Acute GVHD — 45.0 percentage of participants

Primary: Participants no Longer Meeting Criteria for Severe Aplastic Anemia. — 18; 17; 9; 9 participants

Primary: Acute Graft vs Host Disease (GvHD) — 2.7 percentage of participants

Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants

Primary: Composite Success Rate — 100; 75; 84 Percentage of participants

Primary: Incidence of Acute Graft-versus-host Disease (GVHD) — 44.7 percentage of participants

Primary: Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation — 12 participants

Primary: Rates of Acute Cellular Rejection Between Study Group — 4; 2 Number of rejection — p=<0.05

Primary: Patient Survival — 109; 104 Participants